Dopamine Regulates Mobilization of Mesenchymal Stem Cells during Wound Angiogenesis by Shome, Saurav et al.
Dopamine Regulates Mobilization of Mesenchymal Stem
Cells during Wound Angiogenesis
Saurav Shome
1, Partha Sarathi Dasgupta
1*, Sujit Basu
2,3,4*
1Department of Signal Transduction and Biogenic Amines, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India, 2Department of Pathology, Ohio State
University, Columbus, Ohio, United States of America, 3Dorthy M. Davis Heart and Lung Research Institute, Ohio State University, Columbus, Ohio, United States of
America, 4Arthur G. James Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, United States of America
Abstract
Angiogenesis is an important step in the complex biological and molecular events leading to successful healing of dermal
wounds. Among the different cellular effectors of wound angiogenesis, the role of mesenchymal stem cells (MSCs) is of
current interest due to their transdifferentiation and proangiogenic potentials. Skin is richly innervated by sympathetic
nerves which secrete dopamine (DA) and we have recently shown that concentration of DA present in synaptic cleft can
significantly inhibit wound tissue neovascularization. As recent reports indicate that MSCs by mobilizing into wound bed
play an important role in promoting wound angiogenesis, we therefore investigated the effect of DA on the migration of
MSCs in wound tissues. DA acted through its D2 receptors present in the MSCs to inhibit their mobilization to the wound
beds by suppressing Akt phosphorylation and actin polymerization. In contrast, this inhibitory effect of DA was reversed
after treatment with specific DA D2 receptor antagonist. Increased mobilization of MSCs was demonstrated in the wound
site following blockade of DA D2 receptor mediated actions, and this in turn was associated with significantly more
angiogenesis in wound tissues. This study is of translational value and indicates use of DA D2 receptor antagonists to
stimulate mobilization of these stem cells for faster regeneration of damaged tissues.
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Introduction
Angiogenesis, the formation of new blood vessels from pre-
existing ones is a normal physiological process and plays an
important role in wound healing [1–2]. This complex and
dynamic process further involves multiple cellular and molecular
regulators, among which the roles of endothelial cells [1–2] and
endothelial progenitor cells [3–5] have been well documented.
However, recent attention has been drawn to the role of
mesenchymal stem cells (MSCs) in wound angiogenesis and the
healing process [6–10]. MSCs are multipotent stem cells present
in adult bone marrow, umbilical vein and adipose tissue, and these
adult stem cells have the capacity to proliferate and differentiate
into different mesenchymal lineage cells [11–13]. Wound results in
the release of various growth factors and cytokines and these
molecules by acting as chemokines increase the mobility of MSCs
from their sources, thereby facilitating migration of MSCs into
the peripheral blood and from there into wound bed [14–16].
Accumulating MSCs at wounded sites accelerate the process of
wound tissue angiogenesis, an essential physiological step for
successful wound tissue repair by transdifferentiating into different
cell types, which include endothelial cells, the principal struc-
tural component of wound tissue neovessels [8,10,13,17–19].
In addition, these MSCs have the capacity to release various
proangiogenic factors like vascular endothelial growth factor
(VEGF) to support the growth, survival and differentiation of
endothelial cells [9,13,17,19–20].
Previous studies from our laboratory have conclusively demon-
strated that endogenous catecholamine neurotransmitter DA by
acting through its D2 receptors can significantly inhibit angiogen-
esis in malignant tumors [21–24]. Recent studies from our lab-
oratory have also shown that DA by acting via its D2 receptors
negatively influences the process of normal wound healing in a
murine model of full thickness dermal wounds, and treatment with
specific DA D2 receptor antagonist significantly accelerates the
process of neovascularization in wound tissues leading to faster
healing [25]. As recent reports indicate important roles of MSCs in
wound angiogenesis, we therefore investigated whether DA can
regulate this neovascularization process in normal wound tissue by
influencing the mobilization of MSCs into wound site and their
subsequent pro-angiogenic effects during wound healing.
Results
Treatment with specific DA D2 receptor antagonist
following injury significantly increases number of MSCs
(CD34
2 CD45
2 CD105
+ cells) in peripheral blood
Recent studies from our laboratory have shown that treatment
with specific DA D2 receptor antagonist significantly accelerates
the time of wound healing in a murine model of full thickness
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31682normal dermal wounds, and this healing in turn is associated with
increased angiogenesis in wound tissues [25]. Mobilization of
MSCs into wound bed and their subsequent active participation
in wound tissue neovascularization are critical steps towards
successful wound healing [6–8,10,13,17–19]. Therefore, in the
present investigation to explore the regulatory role of DA D2
receptors, if any, on mobilization of MSCs into wound site, the
status of circulating MSCs in peripheral blood of both control and
eticlopride treated back skin-injured mice had been compared
at different time intervals by flow cytometry to determine the effect
of inhibitory action of DA D2 receptors on the profile of circulat-
ing MSCs. The results showed that treatment with DA D2
receptor antagonist eticlopride significantly increased the numbers
of circulating MSCs (immunophenotypically CD34
2 CD45
2
CD105
+ cells) [26] in peripheral blood of wound bearing mice
in comparison to vehicle treated controls at different time intervals
(3, 6, 12, 24, 36 and 48 hours after wounding) (Fig. 1A and 1B). In
both control and treated animals, the number of circulating MSCs
showed a sharp increase that reached peak at 6 hour after creation
of wounds (Fig. 1A). However, this increase in the numbers of
circulating MSCs were significantly higher in DA D2 receptor
antagonist treated mice in comparison to vehicle treated controls
at all time points (Fig. 1B). Similar results were also observed
following treatment with another DA D2 receptor specific anta-
gonist domperidone (results not shown). It is to be noted here that
treatment with other DA receptor antagonists (D1,D 3,D 4 and D5)
had no significant effects on the mobilization of MSCs (results not
shown). This data confirmed that the action of DA was specific
and was mediated through its D2 receptors present in MSCs.
CD34
2 CD45
2 CD105
+ Cells showed osteogenic and
adipogenic differentiation potential in vitro
Mesenchymal stem cells are multipotent in nature and have the
unique ability to differentiate into various cell types among which
osteogenic and adipogenic differentiation are considered as hallmarks
of these adult stem cells [26]. Therefore, to confirm the identity of
CD34
2 CD45
2 CD105
+ cells as MSCs, their osteogenic and
adipogenic differentiation potential wereevaluated. Using lineage cell
depletion kit (Miltenyi Biotec, Germany), mesenchymal lineage cells
were isolated from total bone marrow cells by depletion of cells of
haematopoietic lineage, cultured in MSC media and expanded in vitro
for three passages [27]. Flow cytometry demonstrated that over 95%
of the total cells were phenotypically CD34
2 CD45
2 CD105
+ in
nature, characteristics of MSCs (Fig. 1C). These CD34
2 CD45
2
CD105
+ cells also expressed SSEA-4, a stage-specific embryonic
antigen that identifies adult mesenchymal stem cell population from
the bone marrow [28]. These cells were then cultured in appropriate
induction media to induce osteocytes and adipocytes [29]. In the
initial osteogenic culture, no mineralized cell was detected. However,
after five weeks, mineralized cells positive for von Kossa staining
showing calcium deposition were observed (Fig. 1D) thus indicating
osteogenic differentiation of these cells. Similarly one week after
adipogenic induction, formation of intracellular lipid vacuoles were
detected in these cells. Thereafter, lipid accumulation increased along
with the inductive periods, which was chemically stained by Oil Red
O, a specific staining, which identifies lipid droplets in adipocytes,
thereby, confirming adipocytic nature of these cells (Fig. 1E).
Murine MSCs express DA D2 receptors
To confirm the role of DA D2 receptors in the migration of
MSCs into wound tissue, it was necessary to know whether these
cells expressed DA D2 receptors. Therefore, the presence of DA
D2 receptor was investigated by western blot and flow cytometry.
Western blot analysis of in vitro expanded murine MSCs showed
presence of DA D2 receptors in these cells, which was further
confirmed by flow cytometry analysis (Fig. 2A and 2B). Flow
cytometry of CD45
2 CD34
2 CD105
+ SSEA-4
+ cells confirmed
that almost 86% cells of the total MSC population expressed DA
D2 receptors on their surfaces (Fig. 2A).
Treatment with DA D2 receptor antagonist significantly
accelerated mobilization of exogenously transplanted
MSCs towards wound bed
As it was evident that treatment with DA D2 receptor antagonist
increased the number of circulating MSCs in wound bearing mice
(Fig. 1A and 1B), therefore experiment was undertaken to
determine mobilization of these circulating MSCs cells into the
wound bed, the site where these cells are required to migrate in
order to mediate wound angiogenesis and tissue repair. To
investigate the effect of DA D2 receptor antagonist on the homing
of MSCs into wound site, bone marrow derived and expanded
MSCs (CD34
2 CD45
2 CD105
+ cells) were labeled with BrdU in
culture and were then injected i.v. via the tail veins into both
control and eticlopride treated back skin-injured mice on day
1 after wounding. These cells were injected 2 hrs after DA D2
receptor antagonist treatment. The transplanted MSCs in the
wound bed were identified by BrdU immunoreactivity. Our study
revealed significantly higher number of BrdU labeled MSC
transplants in DA D2 receptor antagonist treated wound tissues
than vehicle treated controls on day 6 after creation of wound and
completion of 4 day treatment schedule (10 mg/kg/day) of
eticlopride (Fig. 2C and 2D).
Increased integration of fluorophore-labeled (CM-Dil)
transplanted MSCs into blood vessels in wound bed
following DA D2 receptor antagonist treatment
Our previous results had shown that treatment with DA D2
receptor antagonist eticlopride significantly increased the wound
healing process by stimulating neovascularization [25]. Interest-
ingly, our present results also revealed that this treatment was
associated with increased number of migrated MSCs into wound
sites (Fig. 2C and 2D). Therefore, we investigated whether this
increased number of mobilized MSCs in wound tissue following
DA D2 receptor antagonist treatment was also associated with
increased incorporation of these cells into the neovessels of heal-
ing wounds. Co-localization studies showed that on day 6 after
wounding and completion of 4 day of eticlopride treatment
schedule, exogenously transplanted MSCs, labeled with fluores-
cent dye CM-Dil (red in colour), had incorporated into the newly
formed blood vessels in wound site (CD31 positive cells, green in
colour) in considerably higher numbers than vehicle treated
controls (Fig. 3A).
Furthermore our results also demonstrated that treatment with
eticlopride in combination with transplanted MSCs resulted in
significantly more angiogenesis in wound tissues in comparisons to
the vehicle treated controls or animals treated with eticlopride or
MSCs alone (Fig. 3B and 3C).
DA through its D2 receptors regulate VEGF induced
migration of MSCs in vitro
In vivo results from the present investigation had shown that
exogenously transplanted BrdU labeled MSCs migrated to the
wound bed in significantly higher numbers in DA D2 receptor
antagonist eticlopride treated wound bearing mice than vehicle
treated controls (Fig. 2C). It was also evident from co-localization
study that greater numbers of these cells had integrated into the
neovessels of the wound bed (Fig. 3A).
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PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31682Figure 1. Treatment with dopamine (DA) D2 receptor specific antagonist significantly increased the number of circulating MSCs in
peripheral blood of wound bearing mice. (A) Effect of eticlopride (DA D2 receptor specific antagonist) on the number of circulating MSCs in
peripheral blood of wound bearing mice. Blood was collected from both the control and eticlopride treated wound bearing mice at different time
intervals after injury, mixed with EDTA, treated with RBC lysis buffer and incubated with anti-CD45, anti-CD34 and anti-CD105 antibodies. Cells were
initially gated to exclude dead cells and debris and then the CD34
2 CD45
2 cell population was selected and evaluated for presence of CD105, a
specific surface marker of MSCs. Results are representative of six separate experiments each yielding similar results. (B) Graph showing that DA D2
receptor antagonist treatment have significant positive regulatory effect on MSC mobilization as significantly higher number of MSCs (CD34
2 CD45
2
CD105
+ cells) was evident in peripheral blood of mice compared to vehicle treated controls at all time points after wounding. (*, P,0.05). (C)
Characterization of MSCs by flow cytometry. Analysis with flow cytometer showed that over 95% cells of the total 3rd passage murine bone marrow
cell populations were positive for both SSEA-4 and CD105 (specific surface markers of MSCs) and negative for CD34 and CD45, thus confirming their
identity as MSCs. BM-MSCs were cultured in appropriate induction media to evaluate osteogenic and adipogenic differentiation potential of these
stem cells and were confirmed by von Kossa staining (D) and Oil-red O staining (E) respectively. (D) To confirm osteogenic differentiation, mineralized
deposits in the extracellular matrix were visualized by von Kossa staining. Differentiated cells were fixed with 4% paraformaldehyde, washed and then
stained with 5% silver nitrate (Sigma) solution in the absence of light at room temperature for 30 minutes. Cells were then exposed to sunlight for
5 minutes and excess silver staining was removed by washing 2–3 times with a 5% sodium thiosulfate solution and ultimately washed with distilled
water. (E) Adipogenic differentiation of cultured MSCs was confirmed by Oil-red O staining. Cells were fixed with 4% paraformaldehyde and washed
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growth factor, which regulates wound angiogenesis [30–33] and che-
motactic migration of MSCs both in vitro and in vivo [14,15,31,34–37],
therefore further experiments were designed in vitro to determine the
direct effect of VEGF on the migration of murine MSCs.
The results showed that the numbers of migrated MSCs
(CD34
2 CD45
2 CD105
+ cells) in the presence of medium alone
(DMEM without FCS) was very low and it increased in the
presence of 30% FCS or VEGF (10 ng/ml) (Fig. 4A). This result
corroborates well with the critical role of VEGF in regulating
chemotaxis of MSCs into wound bed as reported by several
other studies [15,31,34–37]. Therefore, further experiments were
designed in vitro to evaluate the role of DA on VEGF induced
migration of murine MSCs.
Figure 2. Treatment with dopamine (DA) D2 receptor antagonist significantly accelerated mobilization of exogenously
transplanted MSCs towards wound bed. (A) Flow cytometric analysis of DA D2 receptors in murine MSCs. To confirm that CD34
2 CD45
2
CD105
+ SSEA-4
+ cells express DA D2 receptors, in vitro expanded Lin
neg bone marrow cell population (containing CD45
2, CD11b
2 cell populations)
were initially gated to exclude dead cells and debris and then the CD34
2 cell population were selected and these CD34
2 CD45
2 cells were evaluated
for presence of CD105, SSEA-4 and DA D2 receptors. Results showed that almost 86% cells of the total MSC population (both CD34
2 CD45
2 CD105
+
cells and CD34
2 CD45
2 SSEA-4
+ cells) express DA D2 receptors on their surfaces. (B) Western blot analysis of DA D2 receptors in murine BM-MSCs. H4
neuroglioma cell line and sarcoma-180 (S-180) tumor cells were used as positive and negative controls, respectively. (C) Effect of DA D2 receptor
antagonist treatment on mobilization of exogenously transplanted MSCs towards wound site. MSCs were labeled with BrdU in culture and injected
into the tail vein of both control and eticlopride treated back skin-injured mice. After completion of eticlopride treatment, at 6th day the skin from
the wound area was collected and analyzed by immunohistochemistry using BrdU labeling and detection kit (Roche Applied Science). Significantly
higher number of BrdU positive transplanted MSCs are located in the wound bed of eticlopride treated group than vehicle treated control group,
showing DA D2 receptor antagonist treatment has significant positive effect on mobilization of exogenously transplanted MSCs towards wound site.
Original magnifications, 6200. Results are representative of six separate experiments each yielding similar results. (D) Graphical representation
showing significantly higher number of exogenously transplanted MSCs (BrdU positive cells) in wound bed of eticlopride treated groups compared to
vehicle treated controls at day 6 post wounding (*, P,0.05). Number of transplanted MSCs cells was measured by counting the number of BrdU
positive cells in 10 randomly chosen high power microscopic fields within the sections.
doi:10.1371/journal.pone.0031682.g002
with 60% isopropanol. After completely drying the flasks Oil Red O working solution were added and stained for 15 minutes. Then all Oil Red O were
removed and distilled water was added immediately to wash 2 times. Finally, the flasks were viewed under microscope and photographed. Original
magnifications, 6200.
doi:10.1371/journal.pone.0031682.g001
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31682Figure 3. Dopamine (DA) D2 receptor antagonist treatment stimulate incorporation of MSCs into neovessels of wound bed and
subsequent angiogenesis in wound bed. (A) Effect of eticlopride treatment on incorporation of transplanted MSCs into newly formed blood
vessels in wound bed. MSCs were labeled with CM-Dil and injected into the tail vein of both control and eticlopride treated back skin-injured mice. At
day 6, the skin from the wound area was collected and sectioned with cryomicrotome. Frozen sections were immunostained with anti-CD31 antibody
and FITC-conjugated secondary antibody and analyzed to determine the extent of incorporation of transplanted MSCs into blood vessels. Here co-
localization study showed that exogenously transplanted MSCs, labeled with fluorescent dye CM-Dil (red in colour), had integrated into the newly
formed blood vessels (green in colour) in wound site in much greater number following DA D2 receptor antagonist treatment than vehicle treated
controls. Original magnifications, 6200. (B) Effect of MSC transplantation on formation of new blood vessels in wound bed. Immunohistochemical
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which DA is a major catecholamine neurotransmitter found in the
extracellular fluid surrounding neuronal synapses [38–39]. Therefore
in the present investigation, the effect of physiological concentration
of DA (1 mM as observed in neuronal synapses) [40] was evaluated in
regulating VEGF induced migration of MSCs in vitro.
Addition of 1 mM DA in the medium significantly inhibited
VEGF induced migration of MSCs, whereas, when these cells were
pre-treated with 100 mM eticlopride (a specific DA D2 receptor
antagonist), the inhibitory effect of DA on this growth factor
mediated mobilization was abrogated (Fig. 4A). Thus, the in vitro
results showed that physiologicalconcentration of DA as observed in
Figure 4. VEGF regulates migration of murine BM-MSCs through activation of Akt. (A) Effects of VEGF on in vitro migration of MSCs in
transwell chambers. After incubation with MSCs at 37uC for 24 hours, VEGF was added. After overnight incubation cells remaining on the upper face
of the filters were removed with a cotton wool swab and migrated cells that remained on the lower face of the filters were stained with Gill’s
Haematoxylin, counted and photographed. Numbers of migrated cells were counted in 10 high-power fields (HPFs) after subtraction of the basal
migration observed in the presence of DMEM alone (without presence of any growth factor). Dopamine (DA) significantly inhibits VEGF induced
migration of MSCs (*, P,0.05), whereas when cells were pre-treated with 100 mM eticlopride (a specific DA D2 receptor antagonist), the inhibitory
effect of 1 mM DA on VEGF mediated mobilization was abrogated. Results are representative of six separate experiments each yielding similar results.
(B) Silencing of Akt in MSCs by siRNA transfection. After 48 hours of transfection, no expression of Akt was found in MSCs transfected with Akt siRNA
(iAkt) whereas control MSCs in which control siRNA containing scrambled sequence (iScr) was transfected showed similar expression of Akt as normal
non-transfected MSCs. (C) Effect of Akt silencing on VEGF induced migration of MSCs in a chemotaxis assay. Numbers of migrated cells were counted
in 10 high-power fields (HPFs) after subtraction of the basal migration observed in the presence of DMEM alone (without presence of any growth
factor). Silencing of Akt significantly inhibits VEGF induced migration of MSCs (*, P,0.05). Results are representative of six separate experiments each
yielding similar results. (D) Flow cytometric analysis of VEGFR-2 receptors in murine MSCs. To confirm that CD34
2 CD45
2 CD105
+ cells express
VEGFR-2 receptors, CD34
2 cells were selected from in vitro expanded Lin
neg bone marrow cell population (containing CD45
2, CD11b
2 cell
populations) and these CD34
2 CD45
2 cells were evaluated for presence of CD105 and VEGFR-2 receptors. Results showed that almost 89% cells of
the total MSC population (CD34
2 CD45
2 CD105
+ cells) express VEGFR-2 receptors on their surfaces.
doi:10.1371/journal.pone.0031682.g004
staining of CD31, a specific endothelial cell surface marker, shows significantly greater number of microvessels in wound tissue sections of DA D2
receptor antagonist treated mice in comparison to vehicle treated controls at day 6 post wounding. Treatment with MSCs significantly increases
microvessel density in wound bed in comparison to saline treated controls. However, eticlopride treatment along with MSCs transplantation is most
effective in increasing angiogenesis in wound tissue. Original magnifications 6200. (C) Graphical representation showing microvessels density in
wound tissue sections of different experimental groups at day 6 after post wounding (*, P,0.05). Microvessel density (CD31 positive cells) in wound
bed was measured by counting the number of microvessels in 10 randomly chosen high power microscopic fields within the sections.
doi:10.1371/journal.pone.0031682.g003
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31682neuronal synapse [40] inhibits VEGF induced migration of MSCs.
Furthermore, this in vitro result also correlated well with our previous
in vivo observations of eticlopride, a DA D2 receptor antagonist-
mediated increased mobilization of MSCs into wound bed.
DA regulates VEGF induced migration of murine MSCs by
inhibiting Akt phosphorylation
Because neurotransmitter DA by acting through its D2 receptors
significantly inhibited VEGF induced migration of murine MSCs
in vitro (Fig. 4A), we next elucidated the regulatory role of DA
in influencing the key signaling pathway for VEGF induced
mobilization of MSCs into the wound site. Since recent experi-
mental results have shown that activation of Akt increases the
migratory activity of MSCs [41–44], experiments were therefore
designed to dissect the regulatory role of Akt in VEGF induced
migration of MSCs in mice. siRNA transfection was utilized to
knock-down (silence) Akt in MSCs. After 48 hours, western blot
analysis was performed to confirm silencing in Akt siRNA
transfected cells (iAkt) (Fig. 4B).
The role of Akt kinase on growth factor induced mobilization of
murine MSCs was then evaluated by in vitro migration assay of
siRNA transfected (Akt-silenced) MSCs against chemotactic
activity of 10 ng/ml VEGF. Silencing of Akt significantly inhibited
VEGF induced migration of MSCs (Fig. 4C). Furthermore, flow
cytometry analysis showed that murine BM-MSCs also express
VEGFR-2 receptors on their surfaces (Fig. 4D), which corrobo-
rated well with previous observations [45–46] thus showing that
VEGF considerably influences mobilization of murine MSCs by
activating Akt kinase through its VEGFR-2 receptors present on
these cells.
We next elucidated whether DA exerted its inhibitory effects on
the mobilization of MSCs by suppresing the activation of Akt in
these cells. The activation of DA receptors in MSCs by 1 mMo f
DA significantly inhibited VEGF (10 ng/ml) induced phosphor-
ylation of both VEGFR-2 and its downstream signaling molecule
Akt (Fig. 5A and 5B). However, these actions of DA were
abrogated following treatment with 100 mM eticlopride, a DA D2
receptor antagonist (Fig. 5A and 5B). In contrast, no changes were
observed in the expression of total VEGFR-2 and total Akt. These
results indicated that DA through its D2 receptors significantly
inhibited VEGF induced migration of murine MSCs by depho-
sphorylating both VEGFR-2 receptors and its downstream target
Akt kinase in these stem cells.
DA regulates polymerization of actin filaments in
migrating MSCs
Reorganization and active regulation of actin cytoskeleton is an
important event in the migratory response of cells to growth
factors, and phosphorylation of Akt had been implicated to induce
this actin polymerization [43–44].
In our actinpolymerization assay, VEGF stimulated MSCs which
showed high migratory activities [Fig. 4A], was also associated with
changes in the polymerization dynamics of this protein leading to
formation of F-actin [Fig. 5C]. However, no such alterations were
observed in Akt silenced MSCs [Fig. 5C], which also showed
strikingly lower migratory activity against VEGF in comparison to
normal MSCs [Fig. 4C]. These results indicated that Akt regulated
the mobilization of MSCs by changing polymerization dynamics of
actin cytoskeleton.
Furthermore, treatment with 1 mM of DA, which significantly
inhibited VEGF induced migration of MSCs by suppressing
phophorylation of both VEGFR-2 and its downstream signaling
molecule Akt, was also associated with significant actin depolymer-
ization effect leading to the inhibition MSCs migration (Fig. 5D). In
contrast, pre-treatment with specific DA D2 receptor antagonist
eticlopride abolished this DA mediated inhibitory changes in the
actin polymerization dynamics of VEGF treated MSCs. These
results indicated that DA regulated inhibition of VEGF induced
actin polymerization and migration of MSCs were specifically
mediated through its D2 receptors.
Discussion
Angiogenesis is necessary for successful wound healing and
defects in this process leads to delayed healing as observed in
different types of chronic non-healing wounds. During cutaneous
wound repair, the neovessels provide nutrition and oxygen to the
growing tissues and aids in the formation of the provisional wound
matrix. This dynamic physiological process is temporally and
spatially regulated by interactions between different cell types and
other factors present in the wound microenvironment [1–2].
Among the various cellular effectors, the roles of endothelial cells
and endothelial progenitor cells are well established in the process
of angiogenesis [1–5]. In pathological conditions like malignant
tumors, DA can significantly inhibit tumor angiogenesis by
inhibiting VEGF induced proliferation and migration of both
adult and progenitor endothelial cells [21–24]. We have recently
demonstrated that DA can inhibit angiogenesis in normal wound
tissue by inhibiting the expression of HoxD3 and its target a5b1
integrin in adult endothelial cells [25]. DA acted through its D2
receptors [21–24]. However, current attention has been drawn to
the role of MSCs in the formation of neovessels in wound tissues.
Mesenchymal stem cells are either absent or present in
significantly low numbers in the steady state conditions in
circulation. However, their numbers considerably increase after
trauma or injury and this is associated with increased level of
plasma VEGF [14–16]. These circulating cells then migrate to the
site of the injury by the process of chemotaxis and subsequently
incorporate into the newly formed vessels to be transdifferentiated
into endothelial cells [8,10]. Several studies have indicated that
MSCs can differentiate into endothelial cells and are capable of
inducing neoangiogenesis [8,10,47–48]. In addition, these stem
cells also release several pro-angiogenic molecules like VEGF to
recruit inflammatory and progenitor cells to make the wound
tissue microenvironment conducive for neovessel formation and
subsequent healing [9,13,17,19–20,49]. These reports thus clearly
indicate the importance of MSCs in wound tissue angiogenesis.
The bone marrow and the adipose tissue are considered to be the
principal sources of MSCs [11–13,17–20] and both these tissues are
richly innervated by the sympathetic nerves [50–53]. Furthermore,
substantial amount of dopamine is present in the bone marrow
niche as well as adipocytes [24,54]. We have previously reported
that DA by acting through its DA D2 receptors can inhibit the
activity of MMP-9, a potent regulator cell mobilization from bone
marrow to peripheral circulation [24]. Therefore, in the present
study, the increased numbers of MSCs in the circulation of specific
DA D2 receptor antagonist treated wound bearingmice may be due
to inhibition of DA induced suppression of adipose tissue and/or
bone marrow MMP-9 activity. Our study also for the first time
demonstrates the presence of DA D2 receptors in the bone marrow-
derived MSCs.
In the present investigation, in vivo results showed increased
incorporation of exogenously transplanted MSCs into wound bed
after eticlopride treatment. Furthermore, it was well associated
with significantly enhanced angiogenesis. These results corrobo-
rate well with other reports that indicate significant pro-angiogenic
effect of these stem cells [6–10,48–49]. This present study also
Dopamine and Mesenchymal Stem Cells
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31682indicates that the physiological concentration of DA (1 mM) [40]
present in synaptic clefts can inhibit the incorporation of exo-
genously transplanted MSCs into wound bed. Several recent
reports have indicated that VEGF is the prime growth factor that
regulates wound angiogenesis and migration of MSCs both in vitro
and in vivo [14,30–47], therefore in the present investigation while
exploring the effect of DA on MSC mobilization, VEGF was used
in vitro to induce chemotaxis.
Furthermore, phosphorylation of Akt induced by different
growth factors has been shown to be one of the major signaling
pathways regulating migration of MSCs [41–44]. In the present
investigation, DA-mediated inhibition of MSCs migration was
observed due to inhibition of Akt phosphorylation in murine
MSCs. However, this effect of DA was abrogated after treatment
with specific DA D2 receptor antagonist, thereby indicating that
the action of DA was mediated through its DA D2 receptors. Since
Figure 5. Dopamine (DA) through its D2 receptors inhibits VEGF induced migration of BM-MSCs by regulating phosphorylation of
VEGFR-2 and Akt and actin polymerization. (A and B) Effect of DA on VEGF induced phosphorylation of VEGFR-2 and Akt in murine MSCs. Lane
1: Cells stimulated with VEGF (10 ng/ml). Lane 2: Cells pretreated with 1 mM DA before being exposed to VEGF (10 ng/ml). Lane 3: Cells treated with
100 mM eticlopride followed by DA and VEGF. Addition of DA significantly inhibited VEGF induced phosphorylation of both VEGFR-2 receptors and its
downstream target Akt when compared with VEGF treated control. Pre-treatment with eticlopride, abrogated DA induced dephosphorylation of both
VEGFR-2 and Akt. However, expression of total VEGFR-2 and total Akt remained unchanged. Results are representative of six separate experiments
each yielding similar results. (C) In actin polymerization assay, VEGF induced MSCs showed significant polymerization of actin cytoskeleton leading to
formation of F-actin. However, no such alterations were observed in case of Akt silenced MSCs which showed strikingly lower migratory activity
against VEGF than normal MSCs. (D) Effect of DA on VEGF induced actin polymerization in MSCs. Treatment with 1 mM DA had significant inhibitory
effect on actin polymerization dynamics in MSCs when compared to VEGF treated control. However, pre-treatment with specific DA D2 receptor
antagonist eticlopride (100 mM) abrogated the DA induced changes in the actin polymerization dynamics of the VEGF induced MSCs. Original
magnifications, 61000.
doi:10.1371/journal.pone.0031682.g005
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dynamics of actin cytoskeleton, leading to actin polymerization
and subsequently MSCs migration [43–44], we also determined
the effect of DA on actin polymerization dynamics of MSCs. Our
results indicated that DA mediated inhibition of MSC mobiliza-
tion was associated with the inhibition of actin polymerization in
these cells, and treatment with specific DA D2 receptor antagonist
abrogated these effects. This further confirmed that the inhibitory
effect of DA on MSC migration was specifically mediated through
its D2 receptors. In summary, activation of DA D2 receptors in
MSCs resulted in the inhibition of VEGF induced phosphoryla-
tion of Akt, which in turn suppressed actin polymerization and
subsequent migration of these stem cells. Recent studies by other
groups have also shown that activation of the Akt increases the
migratory activity of human MSCs, whereas treatment with PI3K
inhibitor blocks activation of Akt and thereby, significantly inhibits
migration of these cells [44]. Our results also demonstrated that
like human MSCs, Akt also played a critical role in regulating
migration of murine MSCs.
This information generated from our present study indicate for
the first time that physiological concentration of DA can negatively
regulate mobilization of MSCs into wound sites and consequently
influence angiogenesis in wound tissues. This novel finding is of
clinical significance as DA D2 receptor specific antagonists being
presently used for the treatment of other disorders may be utilized
for accelerating mobilization of MSCs to expedite angiogenesis
and hence tissue regeneration.
Materials and Methods
Experimental wound model and treatment
All animal experiments were performed after approval by the
Institutional Animal Care and Use Committees. The experiments
were carried out in full thickness dermal wound bearing normal
Swiss mice (4–6 weeks and weighing 22–25 g). The animals were
anesthetized with intraperitoneal (i.p.) injection of 100 ml solution
containing ketamine and xylazine mixture (2.215 and 0.175 mg,
respectively; Sigma). The dorsal hair of the mouse was shaved
and disinfected with an alcohol (70% ethanol) swab and two
excisional wounds were created at the same cranial-caudal
level on the dorso-medial back of each animal using an 8 mm
dermal punch biopsy. At the end of the surgical procedure, cages
were placed on a heating pad until mice fully recovered from
anesthesia [25].
Following creation of wounds, the wound bearing mice
were divided into two groups. Immediately after wounding, mice
of the treatment group were injected i.p. with 10 mg/kg of
eticlopride, specific DA D2 receptor antagonist (Sigma) in 300ı `l
normal saline and continued for four consecutive days at an
interval of 24 hours. The control group received similar volume
of normal saline only [25]. The experiments were also repeated
with another specific DA D2 receptor antagonist domperidone
(Sigma).
Isolation, purification and expansion of MSCs from
mouse bone marrow
MSCs were separated from bone marrow of normal Swiss
mice by using MACS cell sorting system of Miltenyi Biotec
(Germany). Bone marrow cells were collected by flushing the
femurs and tibias from healthy female mice (6 weeks old). Cells
obtained from bone marrow were incubated with a cocktail of
biotin-conjugated monoclonal antibodies to remove the hema-
topoetic cells and then separated by anti-biotin microbeads-
conjugated secondary antibody. The Lin
neg fraction (containing
pure Mesenchymal lineage cells) was cultured in murine
mesenchymal stem cell expansion medium (Millipore, USA).
After 48 hours, the non-adherent cells were removed and
fresh medium was added to the cells. Medium was changed
every 2 or 3 days. The adherent spindle-shaped cells were further
propagated for three passages [27].
Osteogenic and adipogenic differentiation of in vitro
expanded MSCs
Osteogenic differentiation was induced by culturing confluent
mouse MSCs in a-minimum essential medium (a-MEM) supple-
mented with 10% FCS, 10 mM b-glycerophosphate, 50 mg/ml
ascorbic acid 2-phosphate and 10 nM dexamethasone for 14–28
days. The media was changed every 3–4 days. Osteogenic dif-
ferentiation of murine MSCs was confirmed by staining min-
eralized deposits in the extracellular matrix with von Kossa
staining which stains calcium deposited in ECM [29].
Adipogenic differentiation was induced by culturing confluent
mouse MSCs in a-minimum essential medium (a-MEM) sup-
plemented with 10% FCS, 0.5 mM IBMX (3-isobutyl-1-methyl-
xanthine), 10 mg/ml insulin and 1 mM dexamethasone (all from
Sigma) for 21 days. The media was changed in every 3–4 days.
Adipogenic differentiation of murine MSCs was confirmed by
Oil-red O staining which stains lipid droplets within adipocytes
[29].
Flow cytometry
Antibodies used for flow cytometry analysis were anti-CD45
(FITC-conjugated conjugated; eBioscience), anti-CD34 (APC-
conjugated; eBioscience), anti-CD105 (Phycoerythrin-conjugated;
eBioscience), anti-SSEA-4 (Phycoerythrin-conjugated; R & D
Systems), mouse anti-D2 DA receptor antibody (Santa Cruz), rat
anti-mouse IgG-FITC (eBioscience) and anti-VEGFR-2 antibody
(FITC-conjugated; BD biosciences). In order to determine the
numbers of circulating MSCs in peripheral blood after injury,
blood was collected from both control and DA D2 receptor
antagonist treated wound bearing mice at different time intervals
(3, 6, 12, 24, 36 and 48 hours after injury) by nicking the tip of
the tail. Each time 400 ml blood was taken and mixed with anti-
coagulant to prevent blood clotting. Then the collected blood
samples were treated with RBC lysis buffer to remove RBCs and
then incubated with different antibodies to evaluate the number
of MSCs in circulation. Cells were initially gated to exclude dead
cells and debris, and then the CD34
2 CD45
2 cell population was
selected and evaluated for the presence of CD105, a surface
marker of MSCs. According to the International Society for
Cellular Therapy (ISCT), MSCs are positive for CD105 and
negative for CD34 and CD45 [26]. Thus, the in vitro expanded
spindle shaped Lin
neg cells (containing pure mesenchymal lineage
cells) were examined for the presence or absence of specific
surface markers to confirm their identity. In addition, the
presence of DA D2 receptors and VEGFR-2 receptors on their
surfaces were also determined in these cells by flow cytometry.
Analyses were considered informative when adequate numbers of
events (after acquisition of 10,000 cells per sample) were collected
in the gated cells. Percentage of positive cells was finally
determined after comparing them with matched isotype controls
[25].
Detection of DA D2 receptors in MSCs by western blot
In vitro expanded MSCs were lysed and the protein extracts from
these cells were subjected to SDS-PAGE and then blotted onto
PVDF membranes (Millipore). Mouse anti-D2 DA receptor IgG
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as primary and secondary antibodies respectively. Antibody
reactive bands were detected by enzyme - linked chemilumines-
cence (Pierce) [25].
Examination of the role of DA D2 receptor antagonist on
homing of exogenously transplanted MSCs to the wound
bed
Passage three MSC cultures were maintained at 50%
confluence. 5-Bromo-29-deoxy-uridine (BrdU) labeling reagent
(Roche Applied Science) was added into the culture medium
(1:1000) 72 hours before transplantation. The BrdU labeled MSCs
were then harvested by trypsinization and resuspended in normal
saline for injection. On the first day after wounding, 10
6 live MSCs
were injected into the tail vein of both control and DA D2 receptor
antagonist treated back skin-injured mice after 2 hours of DA D2
receptor antagonist injection. Thereafter, on completion of
treatment schedule on day 6, the skin from the wound area was
collected and the number of BrdU labeled MSCs transplants were
determined immunohistochemically by using BrdU labeling and
detection kit (Roche Applied Science) [55].
Determination of the incorporation of exogenously
transplanted MSCs into newly formed blood vessels in
wound bed
Lipophilic tracer (CM-Dil; Invitrogen Bioservices) was used to
label MSCs [56–57]. The MSCs were trypsinized from their
passage 3 cultures and incubated in the working solution of CM-
Dil (15 mM CM-Dil solution in HBSS) for 5 minutes at 37uC and
then for an additional 15 minutes at 4uC. After labeling, cells were
washed twice with PBS and resuspended in ice-cold normal saline
for injection. On day 1 after wounding, 10
6 live labeled MSCs
were injected into both control and DA D2 receptor antagonist
treated back skin-injured mice via tail vein, two hours after
injection of DA D2 receptor antagonist. On day 6, the wound
tissues were collected, washed in PBS and fixed in OCT
compound at 220uC for 1 hour, and cryostat sections were cut
from the mid-portion of the wounds with a cryomicrotome. Frozen
sections were immunostained with anti-CD31 antibody (Rat anti-
mouse; BD Pharmingen, USA) and FITC-conjugated secondary
antibody (Goat anti-rat; Millipore, USA) or biotin conjugated
secondary antibody (Rabbit anti-rat IgG; Millipore, MA) and
then analyzed either to determine incorporation of CM-Dil
labeled transplanted MSCs into the newly formed blood vessels
in wound bed or microvessel density using ABC staining kit
(Vector Laboratories) and Nova-Red substrate solution (Vector
Laboratories) [25].
In vitro Migration assay of MSCs
Migration assays were performed in transwell dishes (Corning
Costar) 6.5 mm in diameter with 8 mm pore filters. The upper side
of the transwell filter was coated for 1 hour at 37uC with 0.1%
(wt/vol) bovine gelatin (Sigma-Aldrich) in PBS. After incubation
with MSCs (5610
5 cells) at 37uC for 24 hrs, 10 ng/ml VEGF
(ProSpec) was added to the bottom chamber. Migration observed
in the presence of 30% FCS and with medium alone served as
positive and negative controls respectively. After overnight
incubation of the transwell chamber at 37uC, 5% CO2, the upper
side of the filters was carefully washed with cold PBS, and cells
remaining on the upper face of the filters were removed with a
cotton wool swab. Transwell filters were stained using Gill’s
haematoxylin, cut out with a scalpel, and mounted onto glass
slides, putting the lower face on the top. Each experiment was
performed in triplicate. Data were expressed as numbers of total
migrated cells per insert after subtraction of the basal migration
observed in the presence of DMEM alone (without presence of any
growth factor). We investigated the influence of DA (1 mM) on
chemotactic activity of 10 ng/ml VEGF [58].
siRNA Transfection
The MSCs were trypsinized from their 3rd passage culture and
were plated in 6-well plates at a density of 2610
5 cells/well in 2 ml
antibiotic free normal growth medium (Murine Mesenchymal
Stem Cell Expansion Medium; Millipore, USA) and allowed to
attach overnight. The cells were then transfected with Akt siRNA
(mice). Transfection was performed using siRNA transfection
medium and siRNA transfection reagent (Santa Cruz Biotechnol-
ogy) as per the manufacturer’s instruction. Thereafter, following
transfection, the cells were left to further grow for 48 hours and
finally western blot was performed to confirm the silencing of the
Akt using anti-Akt antibody (Santa Cruz Biotechnology) [59]. The
concentration of siRNA was optimized to ensure that it did not
affect cell viability.
To evaluate the role of the Akt in the migratory activity of
MSCs, in vitro migration assay of siRNA transfected (Akt-silenced)
MSCs were undertaken in transwell dishes (Corning Costar,
Cambridge, MA) against chemotactic activity of 10 ng/ml VEGF.
Western blot analysis to evaluate VEGFR-2 and Akt
phosphorylation in MSCs
Anti-VEGFR-2, anti-p-VEGFR-2, anti-Akt and anti-p-Akt
antibodies (Santa Cruz Biotechnology) were used as primary
antibodies. Protein extracts from cells of various experimental
groups were subjected to SDS-PAGE and then blotted onto PVDF
membranes (Millipore, Bedford, MA). Protein loading was verified
by stripping and reprobing the membrane with anti-VEGFR-2
and anti-Akt. Antibody-reactive bands were detected by enzyme-
linked chemiluminescence (Pierce ECL, SuperSignal, Pierce
Biotechnology) [59].
Actin polymerization assay
Cells of various experimental groups were grown on glass
coverslips and fixed in 37uC with 4% paraformaldehyde in PBS
for 10 minutes. The cells were then incubated with 5 ml 0.15 M
glycine solution for 5 minutes and permeabilized with a solution
of 0.1% (v/v) Triton X-100 in PBS for 5 to 10 minutes. Finally,
these cells were incubated with 1 mg/ml FITC-phalloidin (Sigma)
staining solution for 40 minutes at room temperature [60].
Statistical analysis
Data are means of at least 6 different experiments 6 SEM.
Student’s t-test was used to analyze differences between groups. p
value ,0.05 was considered statistically significant [22].
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